177Lu dotatate peptide receptor radionuclide therapy (PRRT) is approved by the FDA for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Key points about 177Lu dotatate PRRT:
- It is indicated for the treatment of adult patients with somatostatin receptor-positive GEP-NETs. This includes tumors originating in the:
- Foregut (stomach, duodenum, jejunum, pancreas, liver, biliary tract)
- Midgut (lower jejunum, ileum, appendix, ascending colon)
- Hindgut (transverse colon, descending colon, sigmoid colon, rectum)
- It targets tumors that express somatostatin receptors 2 (SSTR2).
- It utilizes 177Lu dotatate, which binds to SSTR2 receptors expressed on tumors. The radionuclide lutetium-177 then delivers targeted radiation directly to tumors.
- Approval was based on the NETTER-1 phase 3 trial, which demonstrated significant improvement in progression-free survival compared to high-dose octreotide LAR.
Balance Hormone Clinic provides cutting-edge peptide receptor radionuclide therapy for the treatment of NETs and other hormone-sensitive conditions. Our board-certified medical team has years of experience using the latest PRRT agents, including:
- 177Lu dotatate - FDA-approved for GEP-NETs
- 177Lu DOTA-rosopatamab - Targets both SSTR2 and PSMA receptors
- 225Ac dotatate - Investigational targeted alpha therapy
We personalize PRRT based on your unique cancer profile to deliver optimal outcomes.
Contact us today to find out if you may be a candidate for peptide receptor therapy.
The
FDA approval of 177Lu dotatate PRRT represents a major advance in the treatment of progressive GEP-NETs. Additional key points:
- In the pivotal NETTER-1 trial, 177Lu dotatate significantly improved progression-free survival by over 18 months compared to high-dose octreotide LAR (28.4 months versus 8.4 months).
- Objective response rates were also significantly higher with 177Lu dotatate (18%) versus octreotide LAR (3%).
- Approval applies to the use of 177Lu dotatate every 8 weeks for a total of 4 doses.
- The most common severe side-effects were lymphopenia, neutropenia, thrombocytopenia, and vomiting. These demonstrate the radioactivity's localized anti-tumor effects with minimal non-tumor organ impact.
- Ongoing studies are evaluating use of 177Lu dotatate in combination with other therapies like capecitabine and temozolomide.
Contact our clinic to determine if
177Lu dotatate PRRT is right for you. We provide world-class molecular profiling and precision radionuclide therapy for NETs and neuroendocrine tumors.
